WALTHAM, Mass. , Aug. 16, 2021 (GLOBE NEWSWIRE) — Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease, today announced its financial results for the quarter ended June 30, 2021, and recent events. “It has […]
Financial
LivaNova Announces Early Retirement of $450 Million Term Loan and Executes $125 Million Revolving Credit Facility
LONDON–(BUSINESS WIRE)–LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced the early retirement of its $450 million five-year senior secured term loan (the Term Loan). To retire the Term Loan, LivaNova repaid the $450 million principal amount outstanding, plus accrued interest and an approximately $35.6 million make-whole […]
Acutus Medical Reports Second Quarter 2021 Financial Results
CARLSBAD, Calif., Aug. 12, 2021 (GLOBE NEWSWIRE) — Acutus Medical, Inc. (“Acutus” or the “Company”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today reported results for the second quarter of 2021. Recent Highlights: Reported revenue of $4.7 million in the […]
Acutus Medical Appoints Niamh Pellegrini to Board of Directors
CARLSBAD, Calif., Aug. 12, 2021 (GLOBE NEWSWIRE) — Acutus Medical (“Acutus”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today announced the appointment of Niamh Pellegrini to the Company’s Board of Directors, effective August 10, 2021. Ms. Pellegrini has over 20 […]
Itamar Medical Appoints Marga Ortigas-Wedekind to its Board of Directors
CAESAREA, Israel, Aug. 12, 2021 (GLOBE NEWSWIRE) — Itamar Medical Ltd. (NASDAQ and TASE: ITMR), a leading medical device and digital health company focused on the integration of sleep apnea management into the cardiac patient care pathway, today announced the appointment of Marga Ortigas-Wedekind to its Board of Directors. Ms. Ortigas-Wedekind brings […]
Milestone Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Clinical and Corporate Update
MONTREAL and CHARLOTTE, N.C., Aug. 11, 2021 /PRNewswire/ — Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today reported financial results for the second quarter ended June 30, 2021 and provided a clinical and corporate update. “The second quarter of 2021 was marked by continued progress advancing our […]
BioCardia Reports Second Quarter 2021 Financial Results and Business Highlights
SAN CARLOS, Calif., Aug. 12, 2021 (GLOBE NEWSWIRE) — BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported financial results for the second quarter of 2021 and filed its quarterly report on Form 10-Q for the three and six months […]
Verve Therapeutics Announces Business and Program Highlights and Reports Second Quarter 2021 Financial Results
New Preclinical Base Editing Durability Data and Proprietary GalNAc-targeted Lipid Nanoparticle Delivery Technology Data to be Presented at TIDES in September 2021 VERVE-101 IND-Enabling Studies Ongoing to Support Planned IND Submission in 2022 Successful $306.7 Million IPO Completed to Enable Advancement of Gene Editing Programs for Cardiovascular Disease CAMBRIDGE, Mass., […]
Silence Therapeutics Reports Half-Year 2021 Results
Silence Therapeutics Reports Half-Year 2021 Results Full enrollment achieved for four cohorts of the APOLLO study of SLN360 in healthy individuals living with high levels of lipoprotein(a) Silence to host R&D Day in New York City on October 21, 2021 August 12, 2021 LONDON, Silence Therapeutics plc, AIM: SLN and Nasdaq: SLN (“Silence” or “the Company”), a leader in the discovery, development and delivery […]
PhaseBio Reports Second-Quarter 2021 Financial Results and Recent Business Highlights
Entered exclusive licensing agreement with Alfasigma S.p.A with up to $245 million in milestone payments and tiered royalty payments for development and commercialization of bentracimab in European and other key markets Achieved interim enrollment milestone with first 143 bentracimab patients enrolled in the REVERSE-IT pivotal Phase 3 trial, with top-line […]
Recent
Anaxiom Announces Early Clinical Results from First-in-Human Experience of Novel Minimally Invasive Obesity Device; Advances Toward U.S. Early Feasibility Study
NEW STUDY LINKS GLP-1 MEDICATIONS TO LOWER RISK OF ATRIAL FIBRILLATION, INDEPENDENT OF WEIGHT LOSS
Late-Breaking Data from PRESERVE Trial Evaluates XVIVO’s HOPE Preservation Approach in Heart Transplantation
Popular
- No commented posts yet